PRNewsWire
25 Mar 2026, 13:00 UTC · 25w ago
Verdict
Headline leans bearish. We score SLNO −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Soleno Therapeutics is facing a securities class action lawsuit alleging it conducted sham clinical trials for its sole commercial product, DCCR (VYKAT XR).
So whatAllegations of fraudulent clinical trials strike at the core of a biotech company's valuation, as it threatens the validity of FDA approval and future revenue.
More negative than 99% of claims this week
The lawsuit claims Soleno downplayed serious safety signals, including potential pulmonary edema and heart failure cases during Phase 3 trials.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 98% of claims this week
The complaint alleges that the integrity of the randomized withdrawal study (Study C602), which was the foundation for DCCR's FDA approval, was fundamentally compromised.
More negative than 95% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit alleging sham clinical trials and concealment of safety risks.
More negative than 81% of ticker scores this week
The company is under investigation following a significant reduction in full-year Adjusted EBITDA guidance.
More negative than 81% of ticker scores this week
The company's stock declined significantly after cutting its full-year 2026 adjusted EBITDA guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
1h ago
+69.1%
Price is moving against the score
$53.01 vs $31.34 close before publication (Mar 24) · not market-adjusted
SLNO chart →